A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia.
Hannah Goulart, Elias Jabbour, Nicholas J Short...
https://pubmed.ncbi.nlm.nih.gov/40500616/Actively Recruiting
Led by M.D. Anderson Cancer Center · Updated on 2026-05-20
508
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating how well a combination of chemotherapy drugscladribine, idarubicin, cytarabine, and venetoclaxwork in treating patients with acute myeloid leukemia AML, high-risk myelodysplastic syndrome MDS, or myeloid blast phase chronic myeloid leukemia CML. This phase II trial aims to determine the complete response rate and overall response rate, assess survival outcomes, duration of response, safety, and tolerability of the treatment. The study also explores molecular biomarkers and disease characteristics related to treatment outcomes. Treatment includes an induction phase where patients receive intravenous cladribine and cytarabine for 5 days, and idarubicin for 3 days. Patients with untreated AML and MDS also take venetoclax orally for 7 days. Those with specific FLT3 mutations may receive additional oral targeted drugs, midostaurin or gilteritinib, for varying days. This induction cycle repeats every 28 days for up to 2 cycles if tolerated. The consolidation phase follows with shorter intravenous drug administration over 3 days and oral venetoclax for 7 days, repeated every 28 days for up to 5 cycles. Targeted drugs continue as applicable during consolidation. Participants undergo regular follow-up visits every 6 to 12 months after completing study treatment. Throughout the trial, researchers monitor treatment response, survival, adverse effects, and molecular disease markers. The main measurement is the complete response rate within 12 months. Other assessments include overall survival, event-free survival, and toxicity incidence. The trial lasts up to one year for outcome evaluations, with ongoing long-term follow-up.
CONDITIONS
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
T
Tapan Kadia
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational Combination Chemotherapy | Standard Intensive Chemotherapy |
|---|---|---|
| What is it? | A four-drug intensive chemotherapy regimen combining cladribine, cytarabine, idarubicin, and venetoclax, administered intravenously and orally for newly diagnosed or relapsed AML, high-risk MDS, or CML in blast phase. | Established intensive chemotherapy regimen using cytarabine and an anthracycline (most commonly daunorubicin or idarubicin) known as '7+3' for adults with AML and high-risk MDS. |
| Role in trial | Investigational treatment arm evaluating whether the new combination improves response rates and outcomes in eligible patients. | Not a trial arm; represents current clinical practice outside the study for patients at similar decision points. |
| Primary use | Treating newly diagnosed, relapsed, or refractory AML, high-risk MDS, or CML in myeloid blast phase to improve response and survival. | Treating newly diagnosed or relapsed AML and high-risk MDS to achieve initial remission. |
| How is it given or performed? | Cladribine, cytarabine, and idarubicin are administered intravenously. Venetoclax is given orally. Treatment follows an intensive schedule as defined by protocol. | Cytarabine is administered by continuous intravenous infusion over 7 days. An anthracycline (daunorubicin or idarubicin) is given intravenously on days 1-3. |
| Evidence status | Preliminary clinical evidence from cohort studies suggests high response rates in newly diagnosed and relapsed AML or high-risk MDS, but randomized outcome data are not yet established. | Extensive published evidence shows remission rates of 60-80% in younger adults with AML; long-term survival remains limited, especially for high-risk or older patients. |
| Important limitations | This is an investigational regimen. Randomized evidence is lacking. Additional toxicity from venetoclax and cladribine may occur; long-term outcomes remain unknown. | Standard 7+3 induction is associated with high toxicity, prolonged cytopenias, and limited effectiveness for high-risk or relapsed disease. Poor outcomes in older or adverse-risk patients remain a challenge. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 7 cycles over multiple 28-day periods
Participants receive active treatment with cladribine, idarubicin, cytarabine, and venetoclax. Additional medications such as midostaurin or gilteritinib may be given depending on specific genetic mutations. Treatment includes an induction phase followed by consolidation cycles in the absence of disease progression or unacceptable toxicity.
Multiple visits during each 28-day cycle for infusion and oral medication administration
Duration - Every 6 to 12 months indefinitely
After completion of study treatment, participants are followed up for ongoing monitoring of their health status and response to treatment.
Follow-up visits every 6 to 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Hannah Goulart, Elias Jabbour, Nicholas J Short...
https://pubmed.ncbi.nlm.nih.gov/40500616/Hannah Goulart, Hagop Kantarjian, Gautam Borthakur...
https://pubmed.ncbi.nlm.nih.gov/40193193/Tapan M Kadia, Patrick K Reville, Gautam Borthakur...
https://pubmed.ncbi.nlm.nih.gov/34329576/Kiyomi Morita, Hagop M Kantarjian, Feng Wang...
https://pubmed.ncbi.nlm.nih.gov/29702001/M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor